Applications of hCRF and derivatives thereof in preparing medicament for treating alveolar hypoventilation syndrome

A technology of derivatives and syndromes, applied in the application field of hCRF and its derivatives in the preparation of drugs for the treatment of alveolar hypoventilation syndrome, which can solve the problems that there are no research and reports on drugs for alveolar hypoventilation syndrome

Inactive Publication Date: 2009-08-12
SHANDONG UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] There have been studies on the use of hCRF in the treatment of cerebral edema, but there have been no studies and repo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of hCRF and derivatives thereof in preparing medicament for treating alveolar hypoventilation syndrome
  • Applications of hCRF and derivatives thereof in preparing medicament for treating alveolar hypoventilation syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: Effect of hCRF on Respiration of Rabbits

[0020] 20 New Zealand big-eared white rabbits, aged 6-12 months, weighing 3-4kg. They were randomly divided into two groups, 10 in each group. The control group was given 2 ml of 0.9% normal saline, and the test group was given intravenous injection of hCRF 4 μg / kg. hCRF was dissolved in 2 ml sterile saline before administration. Ventilation (respiratory rate and tidal volume) was measured continuously with a pneumotachometer. The respiratory rate and tidal volume were measured after the respiration of animals in each group reached a steady state, and the measurement period was 40 minutes. The experimental results were compared and analyzed by t-test, the results are shown in Table 1, P<0.05 was considered significant difference.

[0021] Table 1 Effect of hCRF on the respiratory rate and tidal volume of rabbits

[0022]

[0023] * Compared with the control group, P<0.01

[0024] From the above experimental...

Embodiment 2

[0025] Embodiment 2: Mechanism research of hCRF respiratory excitatory effect

[0026] Rabbits were anesthetized with urethane, the vagus nerve was cut off, paralyzed, and mechanically ventilated. hCRF was injected via the fourth ventricle. Record the changes of the neuron tidal volume nVt. An increase in nVt was found, but no effect on expiratory phase duration. The microinjection method was used to inject hCRF into the ventral side of the parabrachial region of the pons, and the expiratory state was recorded. It was found that both nVt and respiratory rate decreased. The effect of hCRF was not significantly affected after ganglion conduction was blocked with tetrachloroindoleamine.

[0027] The above results show that. hCRF may regulate respiratory movement through the central nervous system and play a role in respiratory stimulation.

Embodiment 3

[0028] Example 3: Pharmacodynamic study of hCRF on model animals of hypoventilation

[0029] 30 rabbits, weighing 2.0-2.5kg, regardless of sex, were randomly divided into 3 groups, namely the placebo group, doxapram group, and hCRF group, with 10 rabbits in each group, and were cross-fixed on the rabbit platform after weighing. On, do the neck and one side groin clipping. Urethane (4ml / Kg body weight) anesthetized the ear vein, separated the neck trachea, common carotid artery and femoral artery on one side, and threaded them for later use. The endotracheal tube was intubated and connected to a physiological recorder via a transducer. Heparin 5ml / Kg body weight was injected into the ear vein for systemic heparinized anticoagulation. The common carotid artery was cannulated and connected to a physiological recorder via a transducer. The femoral artery was catheterized in preparation for bloodletting, and the bloodletting from the femoral artery was sent to a blood gas analyz...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses novel application of hCRF and derivatives thereof in drug production, namely, application of the hCRF and derivatives thereof in preparing medicines for treating low alveolar ventilation syndrome. The effective dose of the hCRF is 1-100mug/Kg weight, preferably 2-10 mug/kg weight. The inventor of the invention makes studies on influence of the hCRF and derivatives thereof on respiration of experimental animals, the mechanism of respiration excitation and drug effect thereof on animal patterns suffering from lung hypoventilation. The experiments prove that the hCRF and derivatives thereof are highly effective respiratory stimulants, the safe dose range is wide and the hCRF and derivatives play an obvious role in improving respiration function of the low alveolar ventilation syndrome.

Description

technical field [0001] The invention relates to the application of hCRF and its derivatives in the preparation of medicines for treating alveolar hypoventilation syndrome. Background technique [0002] Alveolar hypoventilation syndrome (alveolar hypoventilation syndrome) refers to the alveolar ventilation volume can not meet the needs of tissue metabolism, resulting in alveolar partial pressure of oxygen and arterial oxygen partial pressure decreased, while arterial partial pressure of carbon dioxide increased. [0003] Many clinical diseases can lead to chronic alveolar hypoventilation, common in: ①Respiratory receptor disease: carotid body dysfunction and trauma, metabolic acidosis. ②Brainstem diseases: bulbar poliomyelitis, cerebral infarction, intracranial neoplasm, demyelinating diseases, long-term use of certain drugs (such as sedatives, anesthetics), primary alveolar hypoventilation syndrome. ③ Spinal cord, peripheral nerve and respiratory muscle diseases: poliomyeli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61K47/48A61P11/16A61K47/54A61K47/59A61K47/60
Inventor 厉保秋
Owner SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap